登录 | 注册    关注公众号  
微信公众号
搜索
 >  Beads>Nucleocapsid protein >MBS-K017

SARS-CoV-2 Nucleocapsid Protein-coupled Magnetic Beads

热销产品推荐:The Magnetic Stand (Cat.No. MB-01 & Cat.No. MB-02) can be used in conjunction with Beads.

ItemsSize (2mg)Size(5mg X 2)
Particle size2 μm2 μm
Physical appearancePowder mixturePowder mixture
Amount of Coupled Protein≈939 pmol (46 μg) Nucleocapsid protein/mg beads≈939 pmol (46 μg) Nucleocapsid protein/mg beads
Binding Capacity>130 pmol (20 μg) Anti-Nucleocapsid antibody/mg beads>130 pmol (20 μg) Anti-Nucleocapsid antibody/mg beads
FormulationPBS, pH7.4, with 10% TrehalosePBS, pH7.4, with 10% Trehalose
Reconstitution2 mL sterile deionized water (1 mg beads/mL)5 mL sterile deionized water (1 mg beads/mL)

背景(Background)

The pre-coupled magnetic beads coupled with biotinylated SARS-CoV-2 Nucleocapsid protein to streptavidin conjugated magnetic beads, which can capture the Anti-SARS-CoV-2 antibody from cell or serum sample. The beads are in uniform size, narrow size distribution with large surface area and unique surface coating, which can help you get the best performance and highly reproducible results. This very first SARS-CoV-2 Nucleocapsid protein-coupled magnetic beads will bring great convenience with minimum non-specific binding and developed protocols. This ready to use products could greatly save your time and hassle.

表达区间及表达系统(Source)

SARS-CoV-2 Nucleocapsid Protein is expressed from human 293 cells (HEK293). It contains AA Met 1 - Ala 419(Accession # QHO62115.1).

应用说明(Application)

This product is intended for immunocapture, biopanning and flow cytometry. This product is produced non-sterile.

重构方法(Reconstitution)

See Certificate of Analysis (CoA) for detailed instruction.

存储(Storage)

Upon receipt, please store the Beads at -20°C for 1 year in lyophilized state.

Please avoid more than 3 freeze-thaw cycles once reconstitution, immediate use after reconstitution is highly recommended.

原理(Assay Principles)

Antibody Purification: 1. Resuspend the lyophilized beads by adding the buffer of choice. 2. Add analyte to the suspension, mix and incubate to enable specific binding of the beads and the target protein. 3. Magnetize beads, remove supernatant, and wash unbound protein fractions to capture target protein-bound beads. 4. Wash, magnetize the beads and collect purified target protein for use in downstream applications.

The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications.

制剂(Formulation)

Please contact us for detailed information.

Contact us for customized product form or formulation.

 

典型数据-Typical Data

Nucleocapsid protein TYPICAL DATA

Immobilized 49 μg SARS-CoV-2 Nucleocapsid protein to 1 mg Beads can bind the Anti-SARS-CoV-2 Nucleocapsid Antibody with an EC50 of 0.6712 μg/mL.

Protocol

Nucleocapsid protein TYPICAL DATA

Accelerated stability test. After placing the lyophilized beads at 37°C for 7 days, binding activity between the SARS-CoV-2 Nucleocapsid Protein-coupled Magnetic Beads (Cat.No. MBS-K017) and the Anti-SARS-CoV-2 Nucleocapsid Antibody showed little deviation from the unaccelerated sample (%RSD<10%). Data were measured on day 0, 3, 7 respectively.

Protocol

Nucleocapsid protein TYPICAL DATA

Freeze-thaw stability test. After different freeze-thaw cycles, binding activity between the SARS-CoV-2 Nucleocapsid Protein-coupled Magnetic Beads (Cat.No. MBS-K017) and the Anti-SARS-CoV-2 Nucleocapsid Antibody showed little deviation from the unfreeze-thaw sample (%RSD<10%). Three freeze-thaw cycles were performed.

Protocol

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Nucleocapsid protein靶点信息
英文全称:Nucleocapsid proteins
中文全称:核壳蛋白
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:1详情
最高研发阶段:临床一期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定